We collected retrospective data from N = 223 patients (mean age 67 ± 16 years; 151 men) undergoing immunotherapy per standard-of-care, whose treatment decisions did not follow RECIST. Imaging data were gathered for up to two years post-baseline, continuously evaluating RECIST-defined progression types. We analyzed co-occurrence patterns using odds ratios of progression events and assessed prognostic impacts with time-varying Cox regression models.
This study investigates whether different types of RECIST-defined tumor progression reflect distinct biological processes or variations of the same progression.
Of 223 patients, 115 (52%) experienced at least one type of progression. Most patients (57%) experienced multiple types of progression. Most patients with only one type of progression did not have follow-up scans to determine if other types of progression would have occurred later. In general, all progression types are likely to co-occur, supported by significant positive odds ratios. New lesions were more frequent early in treatment, while other types showed no clear temporal trends. Non-measurable progression had the strongest association with worse survival (HR, 2.33; CI: 1.45-3.74; p < 0.001), followed by new lesions (HR, 1.73; CI: 1.05-2.86; p = 0.03) and target lesion progression (HR, 1.66; CI: 1.07-2.58; p = 0.02). Non-target lesion progression was rare (9%) and not prognostic.
RECIST-defined progression types often co-occur, suggesting they represent variations of a shared treatment failure process rather than independent events. Future developments should focus on quantitative metrics for progression.
This website uses cookies to ensure you get the best experience on our website.